Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis
- PMID: 17662007
- DOI: 10.1111/j.1468-1331.2007.01799.x
Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis
Abstract
The aim of the study was to examine diagnostic sensitivity and temporal course of intrathecal Borrelia burgdorferi (Bb) antibody production in acute Lyme neuroborreliosis (LNB). We recruited consecutive adult patients with LNB diagnosis based on strict selection criteria. Serum and cerebrospinal fluid (CSFs) were obtained, and clinical examination was performed pre-treatment, and 13 days and 4 months post-treatment. Pre-treatment positive Bb antibody index (AI) was detected in 34 of 43 (79%). All nine pre-treatment Bb AI negative patients, and 26 of 34 pre-treatment Bb AI positive patients reported symptom duration <6 weeks. Eight patients, all Bb AI positive, reported symptom duration of 6 weeks or longer. Consequently, pre-treatment diagnostic sensitivity of Bb AI was 74% when symptom duration was <6 weeks, and 100% when 6 weeks or longer. Three patients converted from negative to positive Bb AI status post-treatment. The six patients who were persistently Bb AI negative had lower CSF cell count and protein at presentation, when compared with the patients with positive Bb AI. In conclusion, the diagnostic sensitivity of Bb AI is suboptimal in acute early LNB. Repeated post-treatment Bb AI testing, to confirm or reject LNB diagnosis, is unreliable, as the majority of initial Bb AI negative patients remained negative at follow-up.
Similar articles
-
CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.J Neurol. 2008 May;255(5):732-7. doi: 10.1007/s00415-008-0785-y. Epub 2008 Mar 17. J Neurol. 2008. PMID: 18344056
-
The diagnostic spectrum in patients with suspected chronic Lyme neuroborreliosis--the experience from one year of a university hospital's Lyme neuroborreliosis outpatients clinic.Eur J Neurol. 2011 Apr;18(4):547-55. doi: 10.1111/j.1468-1331.2010.03229.x. Epub 2010 Oct 27. Eur J Neurol. 2011. PMID: 20977545
-
A prospective study on the role of CXCL13 in Lyme neuroborreliosis.Neurology. 2011 Mar 22;76(12):1051-8. doi: 10.1212/WNL.0b013e318211c39a. Neurology. 2011. PMID: 21422457
-
Clinical aspects of neuroborreliosis and post-Lyme disease syndrome in adult patients.Int J Med Microbiol. 2006 May;296 Suppl 40:11-6. doi: 10.1016/j.ijmm.2005.12.003. Epub 2006 Mar 9. Int J Med Microbiol. 2006. PMID: 16524775 Review.
-
Lyme neuroborreliosis.Handb Clin Neurol. 2013;115:559-75. doi: 10.1016/B978-0-444-52902-2.00032-1. Handb Clin Neurol. 2013. PMID: 23931802 Review.
Cited by
-
Diagnostic Testing in Central Nervous System Infection.Semin Neurol. 2019 Jun;39(3):297-311. doi: 10.1055/s-0039-1688441. Epub 2019 Aug 2. Semin Neurol. 2019. PMID: 31378866 Free PMC article. Review.
-
CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samples.Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):175-179. doi: 10.1007/s10096-021-04350-y. Epub 2021 Oct 9. Eur J Clin Microbiol Infect Dis. 2022. PMID: 34626256 Free PMC article.
-
Lyme arthritis in Southern Norway--an endemic area for Lyme borreliosis.BMC Infect Dis. 2014 Apr 5;14:185. doi: 10.1186/1471-2334-14-185. BMC Infect Dis. 2014. PMID: 24708707 Free PMC article.
-
Lyme neuroborreliosis as a cause of sudden sensorineural hearing loss and facial palsy.Clin Case Rep. 2022 Oct 11;10(10):e6412. doi: 10.1002/ccr3.6412. eCollection 2022 Oct. Clin Case Rep. 2022. PMID: 36245466 Free PMC article.
-
CSF B - lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.J Neurol. 2008 May;255(5):782. doi: 10.1007/s00415-008-0974-8. Epub 2008 Mar 17. J Neurol. 2008. PMID: 27517589
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources